26 September 2020
: Case report 
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus
Unusual clinical course, Diagnostic / therapeutic accidents, Unusual setting of medical care, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
María Fernanda Zurita1BDEF, Adriana Iglesias Arreaga1BEF*, Adriana A Luzuriaga Chavez1F, Luis Zurita2ABDFDOI: 10.12659/AJCR.927304
Am J Case Rep 2020; 21:e927304
Table 1. Demographic and treatment information for lupus patients with COVID-19.
| Characteristics | n=5 (%) |
|---|---|
| 34.4 | |
| 8 | |
| Male | 0 (0) |
| Female | 5 (100) |
| Arterial hypertension | 1 (20) |
| Chronic obstructive pulmonary disease | 0 (0) |
| Type 2 DM | 0 (0) |
| Nervous system disease | 0 (0) |
| Kidney disease | 0 (0) |
| Hydroxychloroquine 200 mg/day | 5 (100) |
| Azithromycin 500 mg/day | 4 (80) |
| Tocilizumab 400 mg/day | 1 (20) |
| Corticosteroids 20 mg/day | 2 (40) |
| Ivermectin 12 mg/day | 0 (0) |
| Low weight molecular heparin 40 mg/day | 1 (20) |
| Type 2 DM – type 2 diabetes mellitus. | |